A novel combined scientific and artistic approach for the advanced characterization of interactomes: The akirin/subolesin model
Resumen: The main objective of this study was to propose a novel methodology to approach challenges in molecular biology. Akirin/Subolesin (AKR/SUB) are vaccine protective antigens and are a model for the study of the interactome due to its conserved function in the regulation of different biological processes such as immunity and development throughout the metazoan. Herein, three visual artists and a music professor collaborated with scientists for the functional characterization of the AKR2 interactome in the regulation of the NF-¿B pathway in human placenta cells. The results served as a methodological proof-of-concept to advance this research area. The results showed new perspectives on unexplored characteristics of AKR2 with functional implications. These results included protein dimerization, the physical interactions with different proteins simultaneously to regulate various biological processes defined by cell type-specific AKR– protein interactions, and how these interactions positively or negatively regulate the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-¿B) signaling pathway in a biological context-dependent manner. These results suggested that AKR2-interacting proteins might constitute suitable secondary transcription factors for cell-and stimulus-specific regulation of NF-¿B. Musical perspective supported AKR/SUB evolutionary conservation in different species and provided new mechanistic insights into the AKR2 interactome. The combined scientific and artistic perspectives resulted in a multidisciplinary approach, advancing our knowledge on AKR/SUB interactome, and provided new insights into the function of AKR2–protein interactions in the regulation of the NF-¿B pathway. Additionally, herein we proposed an algorithm for quantum vaccinomics by focusing on the model proteins AKR/SUB. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Idioma: Inglés
DOI: 10.3390/vaccines8010077
Año: 2020
Publicado en: Vaccines 8, 1 (2020), 77 [27 pp]
ISSN: 2076-393X

Factor impacto JCR: 4.422 (2020)
Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 63 / 140 = 0.45 (2020) - Q2 - T2
Categ. JCR: IMMUNOLOGY rank: 74 / 162 = 0.457 (2020) - Q2 - T2

Factor impacto SCIMAGO: 1.296 - Drug Discovery (Q1) - Immunology (Q1) - Pharmacology (medical) (Q1) - Pharmacology (Q1) - Infectious Diseases (Q1)

Financiación: info:eu-repo/grantAgreement/ES/MINECO/BFU2016-79892-P
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Sanidad Animal (Dpto. Patología Animal)

Creative Commons Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.


Exportado de SIDERAL (2023-09-21-13:01:32)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Artículos > Artículos por área > Sanidad Animal



 Registro creado el 2023-09-21, última modificación el 2023-09-21


Versión publicada:
 PDF
Valore este documento:

Rate this document:
1
2
3
 
(Sin ninguna reseña)